Connect with us

Hi, what are you looking for?

Science & Technology

An Osteoarthritis Drug May Be the Answer to America’s Opioid Crisis

An Osteoarthritis Drug May Be the Answer to America's Opioid Crisis 1

A compound originally intended to treat osteoarthritis pain has shown promise as a means of suppressing opioid addiction. It can reduce tolerance to the drugs, and even offer neuropathic pain relief in its own right.

A drug developed to treat osteoarthritis pain has shown promise as a method of preventing opioid tolerance and physical dependence. With the opioid epidemic still in full effect in the U.S., there’s a dire need for this kind of drug in opioid addiction treatment.

The compound was tested on mice to determine its ability to treat pain and combat addiction. As a control, mice suffering from neuropathic pain were given morphine, which was effective – but they quickly developed a tolerance, much like humans, who tend to require larger doses over time. However, when given a low dose of the experimental compound alongside the morphine, the mice didn’t develop a tolerance. At higher doses, the drug was also able to offer pain relief in its own right.

Another experiment saw mice treated with either morphine alone, or morphine and the experimental drug, before being given naloxone – a medication that blocks the effects of opioids and causes withdrawal symptoms. The osteoarthritis compound was able to make those symptoms less severe.

There are hopes that the experimental drug could be administered alongside opioids to ensure that patients don’t develop an unhealthy tolerance, and provide pain relief with fewer side effects. It could also play a role in helping people who have already grown tolerant to opioids to wean themselves off the drugs.

The compound was found to be ineffective in its in its original implementation as a treatment for osteoarthritis, but during the course of those initial tests, it was deemed safe for people to use. This means that there should be fewer regulatory hurdles to pass ahead of human trials, which will determine whether the drug would actually work in practice for opioid addiction treatment.

Source link

Advertisement. Scroll to continue reading.

You May Also Like


The Facts:The CEO Insys-Therapeutics and four other executives have been found guilty of racketeering with regards to opioid drugs. They falsified information and bribed...